Drug Combination Disappoints in Advanced NSCLC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
JAVELIN Bladder 100 Trial Interviews with Experts at Conferences
Curated by Clinicians: Educational Forum with Videos, Abstracts and Conference Information
Videos April 23, 2021 November 17, 2020 November 16, 2020 October 14, 2020
Conference Coverage
Conference Highlights from Recent Conference Coverage
Petros Grivas, MD, PhD
In Best of Podium presentation at this year’s Southeast Section of the American Urologic Association Virtual Annual Meeting, Dr. Grivas presented pre-specified subgroup analyses of the JAVELIN Bladder 100 trial. Read More
Yohann Loriot, MD, PhD
Avelumab first-line maintenance therapy is approved in the United States for patients with advanced urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy based on significantly prolonged overall survival versus best supportive care alone (median 21.4 months versus 14.3 months; HR 0.69, 95% CI 0.56-0.86) as reported in the phase III JAVELIN Bladder 100 tri
Share this article
Share this article
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 11, 2021 /PRNewswire/ Harbour BioMed ( HBM , HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) and other type of tumors will be enrolled (study no. 4003.1). The objective of this study is to evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 as a single agent in multiple solid tumor types. The part 1 of phase I trial study results have been submitted to European Society of Medical Oncology (ESMO).
AZ/Daiichi Sankyo’s datopotamab deruxtecan demonstrates ‘promising’ early results in TNBC
10th May 2021
AstraZeneca (AZ) and Daiichi Sankyo’s antibody drug conjugate (ACD) datopotamab deruxtecan has demonstrated promising preliminary response and disease control in new data evaluating the therapy among patients with metastatic triple negative breast cancer (TNBC).
The preliminary data, presented at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer virtual congress, comes from the TNBC cohort of AZ/Daiichi’s TROPION-PanTumor01 Phase I study.
Patients in this study had previously received treatment with a median of four prior lines of therapy, with 88% of these patients having received more than two previous lines of treatment.
(Daiichi Sankyo)
Daiichi Sankyo and partner AstraZeneca’s next-gen antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) has show glimmers of efficacy and a reasonable safety profile in its first data release in breast cancer.
Having already seen some positives in its non-small cell lung cancer test, which is further along, Daiichi and AstraZeneca published the first look at Dato-DXd in triple-negative breast cancer (TNBC) at a late-breaking mini oral presentation at the 2021 European Society of Medical Oncology (ESMO) Breast Cancer Virtual Congress conference Saturday.
Nearly one year ago, AZ agreed to pay $1 billion upfront over two years for ex-Japan rights to the drug, which works as an ADC that targets tumor-associated protein TROP2, plus another $5 billion in milestones.